Enovis (NYSE:ENOV) Insider Purchases $20,920.00 in Stock

Posted by Francis Steltz on Jun 19th, 2026

Enovis Corporation (NYSE:ENOV – Get Free Report) insider Oliver Engert purchased 1,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were acquired at an average cost of $20.92 per share, with a total value of $20,920.00. Following the completion of the transaction, the insider owned 53,640 shares in the company, valued at $1,122,148.80. This trade represents a 1.90% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

On Thursday, June 11th, Oliver Engert acquired 1,200 shares of Enovis stock. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00.
On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average price of $23.00 per share, for a total transaction of $23,000.00.
On Monday, June 1st, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average price of $22.22 per share, for a total transaction of $22,220.00.

Enovis Price Performance

Shares of NYSE ENOV opened at $21.95 on Friday. Enovis Corporation has a fifty-two week low of $20.55 and a fifty-two week high of $36.82. The company has a 50 day simple moving average of $23.93 and a two-hundred day simple moving average of $24.32. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -1.10 and a beta of 1.38. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same period last year, the business earned $0.81 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts expect that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Institutional Trading of Enovis

Institutional investors have recently added to or reduced their stakes in the business. Arax Advisory Partners bought a new stake in shares of Enovis in the 4th quarter worth $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares during the last quarter. Danske Bank A S bought a new stake in Enovis in the 3rd quarter worth about $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the 3rd quarter worth about $80,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ENOV. Evercore reissued an “outperform” rating and issued a $36.00 target price on shares of Enovis in a research note on Friday, May 8th. Needham & Company LLC lifted their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. BTIG Research reissued a “buy” rating and set a $39.00 price objective on shares of Enovis in a research report on Friday, May 22nd. Finally, William Blair initiated coverage on shares of Enovis in a research note on Friday, April 17th. They set an “outperform” rating for the company. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $44.50.

Check Out Our Latest Research Report on Enovis

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Featured Stories

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.